Dementia with Lewy bodies — diagnosis and safe prescribing (MEQ)

(i) Diagnosis. Working diagnosis: probable dementia with Lewy bodies. Dementia is present with progressive functional cognitive decline; core features include fluctuating alertness, recurrent well-formed visual hallucinations, long-standing RBD, and spontaneous parkinsonism — meeting McKeith 2017 probable DLB on clinical grounds alone (two or more core features).[1] 1-year rule: cognitive decline and dementia features began before established long-duration PD diagnosis and parkinsonism is recent relative to cognition — this is DLB not PDD. PDD requires dementia after PD established for at least 1 year (Emre criteria frame).[1][2] Differentials: delirium (still exclude medical drivers of acute worsening), Alzheimer disease (less early RBD/fluctuation/VH cluster), late-onset primary psychosis, Charles Bonnet, vascular cognitive impairment, drug-induced parkinsonism.[1][9]

(ii) Assessment and investigations. Collateral for fluctuation and dream enactment; medication review (anticholinergics, any prior antipsychotics); falls/orthostatic symptoms; capacity, driving, carer injury risk from RBD. Cognitive testing with attention/visuospatial emphasis; motor exam; orthostatic BP. Labs as standard dementia screen; ECG before ChEI; MRI structural imaging. 123I-FP-CIT SPECT is an indicative biomarker when diagnosis remains uncertain — reduced striatal uptake supports DLB — but is not mandatory when clinical probable DLB is already clear.[1][7]

(iii) Management. Non-drug first: calm environment, avoid arguing with hallucinations, lighting/orientation, falls prevention, stop anticholinergics.[9] Cholinesterase inhibitor first-line: e.g. rivastigmine 1.5 mg orally twice daily with food, titrate by 1.5 mg twice daily every ≥2 weeks toward 3–6 mg twice daily as tolerated (DLB/PDD trial tradition), or donepezil 5 mg orally daily increasing to 10 mg if tolerated. Monitor nausea, vomiting, weight, bradycardia/syncope, falls, vivid dreams, tremor worsening.[4][5][6][8] Cancel the high-dose IM haloperidol plan — neuroleptic sensitivity can be severe or fatal in Lewy body dementia; high-potency D2 blockade is not first-line for agitation/psychosis here.[3][8][9] If psychosis remains dangerous after non-drug care and ChEI optimisation, specialist low-dose strategies (e.g. clozapine with blood monitoring, or regionally available pimavanserin; cautious low-dose quetiapine with weak efficacy data) — document risk, target symptom, and review; general dementia antipsychotic mortality caution still applies.[8][9][10]

(iv) RBD, prognosis, follow-up. Bedroom safety now (pad environment, consider separate sleeping arrangements if partner injury); melatonin preferred over clonazepam in frail elderly when drug treatment used.[1][9] Progressive course with high falls, institutionalisation, and carer-burden risk; multidisciplinary old-age psychiatry/neurology follow-up; advance care planning, driving/finance review early.[9]